md-medicaldata

Authors

 

Saša Perić¹, Vladan Đorđević<sup>2

1</sup>Klinika za gastroenterologiju i hepatologiju, Vojnomedicinska akademija, Beograd, Srbija / Clinic for Gastroenterology and Hepatology, The Military Medical Academy, Belgrade, Serbia
²Klinika za psihijatrijske bolesti „Dr Laza Lazarević“, Beograd, Srbija / Clinic for Psychiatric Disorders „Dr Laza Lazarević“, Belgrade, Serbia

 

The paper was received on 10.01.2017 / Accepted on 03.02.2017.

 

Correspondence to

Dr Vladan Đorđević, dr sci. med.
Klinika za psihijatrijske bolesti „Dr Laza Lazarević“ Beograd
Višegradska 26, 11 000 Beograd
Tel: +381 64 865 2536; +381 61 6116-475
e-mail: drvladandjordjevic@gmail.com

 

 

Abstract

 

In the treatment of diseases of digestive system accompanied by frequent diarrhea, probiotic monocultures are commonly used. Probiotics (bacteria and yeasts) are able to perform recolonization and renew symbiosis of the digestive system microflora. Probiotic yeasts Saccharomyces boulardii and Lactobacillus plantarum 299v (LP299v) areof particular importance in that sense. Since there are no data in Serbia concerning utilization and efficiency of probiotic cultures in the treatment of diseases of the digestive system, the aim of this study was to examine the experience of doctors at different levels of health care concerning clinical use of probiotics Saccharomyces boulardii monoculture (Bulardi®, Abela Pharm) and Lactobacillus plantarum 299v (LP299v) (Flobian®, Abela Pharm). The study compromised 60 respondents - doctors, employees in institutions of different levels of health care throughout Serbia. The results showed that the most patients were prescribed probiotics the doctors encountered in clinical use of probiotics, particularly the aforementioned probiotic monocultures. The most common indications were diarrheal syndrome, simultaneous antibiotic therapy and irritable colon. The reasons for their great use were the speed of action, and encouraging healthy microflora, without transfer of genetic material - if they were used with antibiotic therapy.

 

Key words

probiotics, Saccharomyces boulardii, Lactobacillus plantarum 299v (LP299v).

 

 

 

Sažetak

 

U lečenju bolesti digestivnog trakta koje su većinom praćene učestalim dijarejama, najčešće se koriste probiotske monokulture. Probiotici (bakterije i kvasnice) su sposobni da izvrše rekolonizaciju i obnove simbiozu mikroflore digestivnog sistema. Od naročitog značaja su probiotske kulture Saccharomyces boulardii i Lactobacillus plantarum 299v (LP299v). Budući da u Srbiji ne postoje podaci o stepenu korišćenja probiotskih monokultura i zapaženoj efikasnosti u lečenju bolesti digestivnog trakta, cilj ove studije bio je da se ispita iskustvo lekara na različitim nivoima zdravstvene zaštite u kliničkoj primeni probiotskih monokultura Saccharomyces boulardii (Bulardi®, Abela Pharm) i  Lactobacillus plantarum 299v (LP299v) (Flobian®, Abela Pharm). Istraživanjem je obuhvaćeno 60 ispitanika - lekara, zaposlenih u ustanovama na različitim nivoima zdravstvene zaštite širom Srbije. Rezultati su pokazali da većina pacijenta sa kojima se lekari susreću u kliničkoj praksi koriste probiotike, a naročito pomenute probiotske monokulture. Najčešća područja primene bila su dijarejni sindrom, istovremena antibiotska terapija i iritabilni kolon. Razlozi za njihovu čestu upotrebu bili su brzina delovanja i podsticanje zdrave mikroflore, kao i nepostojanje transfera genetskog materijala, uz istovremenu primenu sa antibiotskom terapijom.

 

 

Ključne reči

probiotici, Saccharomyces boulardii, Lactobacillus plantarum 299v (LP299v).

 

 

 

References

 

1. Institut za javno zdravlje Srbije „Dr Milan Jovanović Batut“. Republika Srbija - Odabrani zdravstveni pokazatelji za 2005. godinu. Beograd, 2007.
2. Institut za javno zdravlje Srbije „Dr Milan Jovanović Batut“. Izveštaj o zaraznim bolestima u Republici Srbiji za 2014. godinu. Beograd, 2015.
3. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotic - Saccharomyces boulardii. Aliment Pharmacol Ther 2007; 26(83): 767-78.
4. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2015; 42(4): 793-801.
5. Szajewska H, Horvat A, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41(5): 1237-45
6. Niedzil K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus Plantarum 299v in patients with irritable bowel syndrome. Eur J Gastroenterol. Hepatology 2001; 13: 1143-7.
7. Ministarstvo zdravlja Republike Srbije i Institut za javno zdravlje Srbije “Dr Milan Jovanović Batut”. Rezultati istraživanja zdravlja stanovništva Srbije - 2013. godina. Beograd, 2014.
8. Eurostat. Health Care Database. Dostupno na: http://ec.europa.eu/eurostat/web/health/health-care/data/database?p_p_id=NavTreeportletprod_WAR_NavTreeportletprod_INSTANCE_Opsvz5FrUpNr&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1
9. Samore MH. Epidemiology of nosocomial Clostridium difficile infection. Compr Ther 1993; 19(4): 151−6.
10. Bojanjić J, Marković-Denić Lj, Mijović B. Epidemiološke karakteristike bolničkih dijareja povezanih sa Clostridium difficile-om. Med Čas (Krag) / Med J (Krag) 2013; 47(2): 85-90.
11. Kelesidis T. et al.  Efficacu and safety Saccharomyces boulardii for prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol 2012; 5(2): 111-25.
12. Duccrote P. et al. Lactobacillus Plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. Wolrd J Gastroenterol 2012; 8(30): 4012-18.

UDK: 615.246.03
COBISS.SR-ID 230576396

PDF Perić S. and Đorđević V. •MD-Medical Data 2017;9(1): 057-061